A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL) (clinicaltrials.gov) - Oct 17, 2026 - P1 | N=45 | Not yet recruiting | Sponsor: Heidelberg University
New P1 trial • Astrocytoma • Brain Cancer • Oncology • Solid Tumor
|